Sarah James
Stock Analyst at Cantor Fitzgerald
(1.95)
# 3,084
Out of 5,182 analysts
310
Total ratings
34.06%
Success rate
-7.65%
Average return
Main Sectors:
Stocks Rated by Sarah James
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TBRG TruBridge | Downgrades: Neutral | $25 → $26 | $25.72 | +2.06% | 7 | Apr 24, 2026 | |
| NYXH Nyxoah | Reiterates: Overweight | $11 | $3.00 | +266.67% | 1 | Mar 23, 2026 | |
| DCGO DocGo | Reiterates: Overweight | $3 | $0.69 | +336.17% | 9 | Mar 17, 2026 | |
| HCAT Health Catalyst | Maintains: Neutral | $4 → $3 | $1.37 | +118.98% | 9 | Mar 13, 2026 | |
| UHS Universal Health Services | Maintains: Neutral | $250 → $229 | $179.51 | +27.57% | 28 | Feb 27, 2026 | |
| MDXG MiMedx Group | Maintains: Overweight | $12 → $8 | $3.34 | +139.52% | 1 | Feb 17, 2026 | |
| HUM Humana | Maintains: Neutral | $290 → $201 | $223.62 | -10.12% | 22 | Feb 12, 2026 | |
| MOH Molina Healthcare | Maintains: Neutral | $180 → $144 | $179.22 | -19.65% | 15 | Feb 9, 2026 | |
| CNC Centene | Reiterates: Neutral | $41 | $43.50 | -5.75% | 17 | Feb 9, 2026 | |
| HCA HCA Healthcare | Maintains: Overweight | $525 → $588 | $445.77 | +31.91% | 22 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $22 → $17 | $28.15 | -39.61% | 18 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $78 → $95 | $78.36 | +21.24% | 16 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $190 → $245 | $185.53 | +32.05% | 23 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $36 | $14.54 | +147.59% | 13 | Oct 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $440 | $354.69 | +24.05% | 18 | Aug 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $365 | $282.58 | +29.17% | 22 | Aug 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $28 | $18.41 | +52.09% | 15 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $485 | $356.13 | +36.19% | 20 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $15 | $4.57 | +228.23% | 11 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $10 | $5.85 | +70.94% | 2 | Aug 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $133 | $150.05 | -11.36% | 6 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $42 | $22.30 | +88.34% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $6 → $5 | $8.10 | -38.27% | 2 | Sep 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $5 | $6.75 | -25.93% | 2 | Aug 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $21 | $20.95 | +0.24% | 3 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $39 | $57.75 | -32.47% | 1 | Aug 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $193 | $77.20 | +150.00% | 2 | Sep 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $2.81 | - | 2 | Mar 1, 2017 |
TruBridge
Apr 24, 2026
Downgrades: Neutral
Price Target: $25 → $26
Current: $25.72
Upside: +2.06%
Nyxoah
Mar 23, 2026
Reiterates: Overweight
Price Target: $11
Current: $3.00
Upside: +266.67%
DocGo
Mar 17, 2026
Reiterates: Overweight
Price Target: $3
Current: $0.69
Upside: +336.17%
Health Catalyst
Mar 13, 2026
Maintains: Neutral
Price Target: $4 → $3
Current: $1.37
Upside: +118.98%
Universal Health Services
Feb 27, 2026
Maintains: Neutral
Price Target: $250 → $229
Current: $179.51
Upside: +27.57%
MiMedx Group
Feb 17, 2026
Maintains: Overweight
Price Target: $12 → $8
Current: $3.34
Upside: +139.52%
Humana
Feb 12, 2026
Maintains: Neutral
Price Target: $290 → $201
Current: $223.62
Upside: -10.12%
Molina Healthcare
Feb 9, 2026
Maintains: Neutral
Price Target: $180 → $144
Current: $179.22
Upside: -19.65%
Centene
Feb 9, 2026
Reiterates: Neutral
Price Target: $41
Current: $43.50
Upside: -5.75%
HCA Healthcare
Jan 28, 2026
Maintains: Overweight
Price Target: $525 → $588
Current: $445.77
Upside: +31.91%
Dec 3, 2025
Maintains: Neutral
Price Target: $22 → $17
Current: $28.15
Upside: -39.61%
Oct 30, 2025
Maintains: Overweight
Price Target: $78 → $95
Current: $78.36
Upside: +21.24%
Oct 29, 2025
Maintains: Overweight
Price Target: $190 → $245
Current: $185.53
Upside: +32.05%
Oct 7, 2025
Reiterates: Overweight
Price Target: $36
Current: $14.54
Upside: +147.59%
Aug 26, 2025
Reiterates: Overweight
Price Target: $440
Current: $354.69
Upside: +24.05%
Aug 26, 2025
Reiterates: Overweight
Price Target: $365
Current: $282.58
Upside: +29.17%
Aug 8, 2025
Maintains: Overweight
Price Target: $26 → $28
Current: $18.41
Upside: +52.09%
Apr 23, 2025
Reiterates: Overweight
Price Target: $485
Current: $356.13
Upside: +36.19%
Mar 11, 2025
Reiterates: Overweight
Price Target: $15
Current: $4.57
Upside: +228.23%
Aug 20, 2024
Reiterates: Overweight
Price Target: $10
Current: $5.85
Upside: +70.94%
Mar 6, 2024
Initiates: Equal-Weight
Price Target: $133
Current: $150.05
Upside: -11.36%
Aug 22, 2023
Reiterates: Overweight
Price Target: $42
Current: $22.30
Upside: +88.34%
Sep 15, 2022
Maintains: Equal-Weight
Price Target: $6 → $5
Current: $8.10
Upside: -38.27%
Aug 19, 2022
Maintains: Overweight
Price Target: $7 → $5
Current: $6.75
Upside: -25.93%
Aug 8, 2022
Maintains: Overweight
Price Target: $14 → $21
Current: $20.95
Upside: +0.24%
Aug 12, 2021
Initiates: Overweight
Price Target: $39
Current: $57.75
Upside: -32.47%
Sep 15, 2017
Upgrades: Overweight
Price Target: $193
Current: $77.20
Upside: +150.00%
Mar 1, 2017
Downgrades: Underweight
Price Target: n/a
Current: $2.81
Upside: -